Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
Universal Health beats Q2 revenue estimates. cuts FY profit view

Universal Health beats Q2 revenue estimates. cuts FY profit view

ReutersReuters2026/07/27 20:25
By:Reuters


Overview

  • U.S. hospital operator's Q2 revenue rose 8.3%, beating analyst expectations

  • Adjusted EPS for Q2 rose to $5.98

  • Company repurchased 1.89 mln shares for $320.3 mln in Q2


Outlook

  • Universal Health revises 2026 net revenue forecast to $18.501 bln-$18.762 bln, slightly higher than prior forecast

  • Company now sees 2026 adjusted EBITDA, net of NCI, at $2.610 bln-$2.717 bln, lower than prior forecast

  • Universal Health expects 2026 adjusted EPS-diluted of $22.28-$23.65, lower than earlier forecast


Result Drivers

  • ACUTE CARE GROWTH - Co said same-facility acute care hospitals saw adjusted admissions rise 2.9% and net revenue per adjusted admission increase 3.0% in Q2

  • BEHAVIORAL HEALTH REVENUE - Co said same-facility behavioral health facilities saw net revenue per adjusted admission rise 7.1% in Q2

  • MEDICAID PROGRAM IMPACT - Q2 results included a $100 mln favorable pre-tax impact from the Florida Medicaid managed care directed payment program


Company press release: ID:nPn5TDzZpa


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

Beat

$4.64 bln

$4.58 bln (15 Analysts)

Q2 EPS

$5.98


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 7 "strong buy" or "buy", 14 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the healthcare facilities services peer group is "buy."

  • Wall Street's median 12-month price target for Universal Health Services Inc is $202.00, about 29.7% above its July 24 closing price of $155.75

  • The stock recently traded at 6 times the next 12-month earnings vs. a P/E of 7 three months ago


Reuters Recommended Reads

  • July 27 - Ensign Group Q2 profit beats on higher occupancy rates

  • July 27 - Sleep apnea pill developer Apnimed targets $608 million valuation in US IPO

  • July 27 - AstraZeneca drug prices evolving in response to Trump policy, executive says


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!